This was an exploratory analysis of data from a 2-year , randomized , double-blind study of the dipeptidyl peptidase-4 inhibitor linagliptin 5mg once daily ( n = 764 ) versus the sulphonylurea glimepiride 1-4mg once daily ( n = 755 ) in patients with type 2 diabetes uncontrolled by metformin .